LVPEIi008-A

LVIP02-SD1-2

General

Cell Line

hPSCreg name LVPEIi008-A
Cite as:
LVPEIi008-A (RRID:CVCL_D6MW)
Alternative name(s)
LVIP02-SD1-2
Cell line type Human induced pluripotent stem cell (hiPSC)
Similar lines No similar lines found.
Last update 21st August 2024
User feedback
No feedback available yet.

Login to share your feedback, experiences or results with the research community.

Provider

Generator L.V. Prasad Eye Institute (LVPEI)
Owner L.V. Prasad Eye Institute (LVPEI)
Distributors
Derivation country India

External Databases

BioSamples SAMEA115085113
Cellosaurus CVCL_D6MW
Wikidata Q127382717

General Information

Publications
* Is the cell line readily obtainable for third parties?
Yes
Research use: allowed
Clinical use: not allowed
Commercial use: allowed
Additional restrictions:

Terms and conditions apply for commercial use

Donor Information

General Donor Information

Sex male
Age of donor (at collection) 25-29
Ethnicity Asian Indian (26 year old)

Phenotype and Disease related information (Donor)

Diseases A disease was diagnosed.
Stargardt Disease, Type 1 (STGD1), Autosomal Recessive Macular Dystrophy, Type 2 (ARMD2), Cone-Rod Dystrophy, Type 3 (CORD3), Juvenile Macular Dystrophy (JMD).
The donor is a carrier of a disease-associated mutation and affected.
Stage
Retinal degeneration and total blindness.
Synonyms
  • Stargardt 1
  • fundus flavimaculatus
  • Stargardt disease 1
  • Stargardt macular dystrophy
  • juvenile onset macular degeneration
show more synonyms
Family history Positive history of consanguinity
Is the medical history available upon request? Yes
Is clinical information available? Yes

Karyotyping (Donor)

Has the donor karyotype been analysed?
Yes
Karyotyping method: G-Banding

Other Genotyping (Donor)

Is there genome-wide genotyping or functional data available?
No

Donor Relations

Other cell lines of this donor
All cell lines of this donor's relatives

External Databases (Donor)

BioSamples SAMEA115172671

Ethics

Has informed consent been obtained from the donor of the embryo/tissue from which the pluripotent stem cells have been derived? Yes
Was the consent voluntarily given? Yes
Has the donor been informed that participation will not directly influence their personal treatment? Yes
Can you provide us with a copy of the Donor Information Sheet provided to the donor? No
Please provide contact information of the holder of the original Donor Information Sheet. indumathi@lvpei.org
Do you (Depositor/Provider) hold the original Donor Consent Form? Yes
Alternatives to consent are available? No
Is there other documentation provided to the donor for consenting purposes? No
Confirm that consent was obtained by a qualified professional Yes
Has the donor agreed to be re-contacted? Unknown
Has the donor been informed about how her/his data will be protected? Yes
Please indicate whether the data associated with the donated material has been pseudonymised or anonymised. pseudonymised
Does consent explicitly allow the derivation of pluripotent stem cells? Yes
Does consent expressly prevent the derivation of pluripotent stem cells? No
Does consent pertain to a specific research project? No
Does consent permit unforeseen future research, without further consent? Yes
Does the consent permit uses of donated embryo/tissue or derived cell line intended for clinical treatment or human applications? Yes
Does consent expressly prevent development of commercial products? No
Does consent expressly prevent financial gain from any use of the donated embryo/tissue, including any product made from it? No
Does consent expressly permit storage of donated embryo/tissue for an unlimited time? No
Does consent expressly permit storage of cells derived from the donated embryo/tissue for an unlimited time? Yes
Does consent prevent the DONATED BIOSAMPLE from being made available to researchers anywhere in the world? No
Does consent prevent CELLS DERIVED FROM THE DONATED BIOSAMPLE from being made available to researchers anywhere in the world? No

Does consent permit research by

an academic institution? Yes
a public organisation? Yes
a non-profit company? Yes
a for-profit corporation? Yes
Does consent expressly permit collection of genetic information? Yes
Does consent expressly permit storage of genetic information? Yes
Does consent prevent dissemination of genetic information? No
Has the donor been informed that their donated biosample or derived cells may be tested for the presence of microbiological agents / pathogens? Yes
Has the donor consented to receive information discovered during use of donated embryo/tissue that has significant health implications for the donor? Yes
How may genetic information associated with the cell line be accessed? Controlled Access
Will the donor expect to receive financial benefit, beyond reasonable expenses, in return for donating the biosample? No
Does the consent anticipate that the donor will be notified of results or outcomes of any research involving the donated samples or derived cells? Yes
Does the consent permit the donor, upon withdrawal of consent, to stop the use of the derived cell line(s) that have already been created from donated samples? Yes
Does the consent permit the donor, upon withdrawal of consent, to stop delivery or use of information and data about the donor? Yes
Does consent permit access to medical records of the donor? No
Does consent permit access to any other source of information about the clinical treatment or health of the donor? No
Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the Research Protocol including the consent provisions? Yes
Name of accrediting authority involved? IEC,IC-SCR
Approval number IEC : LEC-08011; LEC-BHR-P-06-22-878; IC-SCR : 04-15-016; 05-21-013.
Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the PROPOSED PROJECT, involving use of donated embryo/tissue or derived cells? Yes
Name of accrediting authority involved? IEC,IC-SCR
Approval number IEC : LEC-08011; LEC-BHR-P-06-22-878; IC-SCR : 04-15-016; 05-21-013.
Do you have obligations to third parties in regard to the use of the cell line? No
Are you aware of any further constraints on the use of the donated embryo/tissue or derived cells? No
Is there an MTA available for the cell line? Yes
For generation of the cell line, who was the supplier of any recombined DNA vectors or commercial kits used? Addgene
Are you aware of any constraints on the use or distribution of the cell line from the owner or any parties identified in the query above? Yes
Constraints for use or distribution For research use only

hIPSC Derivation

General

Source cell type
Dermal fibroblasts are the major cell type in dermis and are commonly accepted as terminally differentiated cells.
Source cell origin
An organ that constitutes the external surface of the body. It consists of the epidermis, dermis, and skin appendages.
Synonyms
  • Skin
  • Human Skin
  • SKIN
  • Integument
  • Skin, total
  • Skin, NOS
  • Skin structure (body structure)
  • entire skin
  • skin of body
  • skin organ
show more synonyms
Source cell type (free text) Full thickness skin punch biopsy was taken from the retro auricular surface to establish Human Dermal Fibroblast (HDF) cultures.
Age of donor (at collection) 25-29
Collected in 2008
Passage number reprogrammed 4

Reprogramming method

Vector type Non-integrating
Vector Episomal
Genes
Is reprogramming vector detectable?
No
Methods used
PCR
Notes on reprogramming vector detection The loss of episomal plasmids and transgenes was further confirmed by genomic PCR and was found to be undetectable beyond P15
Files and images showing reprogramming vector expressed or silenced

Vector free reprogramming

Type of used vector free reprogramming factor(s)
None

Other

Selection criteria for clones Manual picking and passaging till Passage 5. The stably expanding clones are subsequently passaged as cell suspensions prepared using 1X cell dissociation solution (1X DPBS containing 0.5 mM EDTA and 30 mM NaCl) treatment for 6-7 minutes.
Derived under xeno-free conditions
Yes
Derived under GMP?
Yes
Available as clinical grade?
No

Culture Conditions

Surface coating Vitronectin
Feeder cells
No
Passage method Enzyme-free cell dissociation
EDTA
CO2 Concentration 5 %
Medium Essential 8™
Has Rock inhibitor (Y27632) been used at passage previously with this cell line?
Yes
Has Rock inhibitor (Y27632) been used at cryo previously with this cell line?
No
Has Rock inhibitor (Y27632) been used at thaw previously with this cell line?
Yes

Characterisation

Analysis of Undifferentiated Cells
Marker Expressed Immunostaining RT-PCR Flow Cytometry Enzymatic Assay Expression Profiles
Score:
Marker Present Absent
mCpG
OCT4
Differentiation Potency
Endoderm
Ont Id: NCIT_C12706
In vitro spontaneous differentiation
Marker Expressed
GATA6
Yes
AFP
Yes
Mesoderm
Ont Id: UBERON_0000926
In vitro spontaneous differentiation
Marker Expressed
ACTA2
Yes
MSX2
Yes
Ectoderm
Ont Id: UBERON_0000924
In vitro spontaneous differentiation
Marker Expressed
PAX6
Yes
SOX1
Yes

Microbiology / Virus Screening

Mycoplasma Negative

Genotyping

Karyotyping (Cell Line)

Has the cell line karyotype been analysed?
Yes
Normal Karyotype 46,XY
Passage number: 12
Karyotyping method: G-Banding

Other Genotyping (Cell Line)